Riociguat treatment for portopulmonary hypertension: a subgroup analysis from the PATENT-1/-2 studies

In patients with portopulmonary hypertension (n = 13) included in the 12-week randomized placebo-controlled PATENT-1 trial, riociguat was well tolerated and improved 6-min walking distance (6MWD), World Health Organization functional class (WHO FC), and other efficacy parameters; 6MWD and WHO FC imp...

Descripción completa

Detalles Bibliográficos
Autores principales: Cartin-Ceba, Rodrigo, Halank, Michael, Ghofrani, Hossein-Ardeschir, Humbert, Marc, Mattson, John, Fritsch, Arno, Krowka, Michael
Formato: Online Artículo Texto
Lenguaje:English
Publicado: SAGE Publications 2018
Materias:
Research Letter
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5987907/
https://www.ncbi.nlm.nih.gov/pubmed/29565224
http://dx.doi.org/10.1177/2045894018769305
_version_ 1783329205954543616
author Cartin-Ceba, Rodrigo
Halank, Michael
Ghofrani, Hossein-Ardeschir
Humbert, Marc
Mattson, John
Fritsch, Arno
Krowka, Michael
author_facet Cartin-Ceba, Rodrigo
Halank, Michael
Ghofrani, Hossein-Ardeschir
Humbert, Marc
Mattson, John
Fritsch, Arno
Krowka, Michael
author_sort Cartin-Ceba, Rodrigo
collection PubMed
description In patients with portopulmonary hypertension (n = 13) included in the 12-week randomized placebo-controlled PATENT-1 trial, riociguat was well tolerated and improved 6-min walking distance (6MWD), World Health Organization functional class (WHO FC), and other efficacy parameters; 6MWD and WHO FC improvements were sustained over two years in the open-label extension, PATENT-2.
format Online
Article
Text
id pubmed-5987907
institution National Center for Biotechnology Information
language English
publishDate 2018
publisher SAGE Publications
record_format MEDLINE/PubMed
spelling pubmed-59879072018-06-07 Riociguat treatment for portopulmonary hypertension: a subgroup analysis from the PATENT-1/-2 studies Cartin-Ceba, Rodrigo Halank, Michael Ghofrani, Hossein-Ardeschir Humbert, Marc Mattson, John Fritsch, Arno Krowka, Michael Pulm Circ Research Letter In patients with portopulmonary hypertension (n = 13) included in the 12-week randomized placebo-controlled PATENT-1 trial, riociguat was well tolerated and improved 6-min walking distance (6MWD), World Health Organization functional class (WHO FC), and other efficacy parameters; 6MWD and WHO FC improvements were sustained over two years in the open-label extension, PATENT-2. SAGE Publications 2018-03-22 /pmc/articles/PMC5987907/ /pubmed/29565224 http://dx.doi.org/10.1177/2045894018769305 Text en © The Author(s) 2018 http://creativecommons.org/licenses/by-nc/4.0/ Creative Commons Non Commercial CC BY-NC: This article is distributed under the terms of the Creative Commons Attribution-NonCommercial 4.0 License (http://www.creativecommons.org/licenses/by-nc/4.0/) which permits non-commercial use, reproduction and distribution of the work without further permission provided the original work is attributed as specified on the SAGE and Open Access pages (https://us.sagepub.com/en-us/nam/open-access-at-sage).
spellingShingle Research Letter
Cartin-Ceba, Rodrigo
Halank, Michael
Ghofrani, Hossein-Ardeschir
Humbert, Marc
Mattson, John
Fritsch, Arno
Krowka, Michael
Riociguat treatment for portopulmonary hypertension: a subgroup analysis from the PATENT-1/-2 studies
title Riociguat treatment for portopulmonary hypertension: a subgroup analysis from the PATENT-1/-2 studies
title_full Riociguat treatment for portopulmonary hypertension: a subgroup analysis from the PATENT-1/-2 studies
title_fullStr Riociguat treatment for portopulmonary hypertension: a subgroup analysis from the PATENT-1/-2 studies
title_full_unstemmed Riociguat treatment for portopulmonary hypertension: a subgroup analysis from the PATENT-1/-2 studies
title_short Riociguat treatment for portopulmonary hypertension: a subgroup analysis from the PATENT-1/-2 studies
title_sort riociguat treatment for portopulmonary hypertension: a subgroup analysis from the patent-1/-2 studies
topic Research Letter
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5987907/
https://www.ncbi.nlm.nih.gov/pubmed/29565224
http://dx.doi.org/10.1177/2045894018769305
work_keys_str_mv AT cartincebarodrigo riociguattreatmentforportopulmonaryhypertensionasubgroupanalysisfromthepatent12studies
AT halankmichael riociguattreatmentforportopulmonaryhypertensionasubgroupanalysisfromthepatent12studies
AT ghofranihosseinardeschir riociguattreatmentforportopulmonaryhypertensionasubgroupanalysisfromthepatent12studies
AT humbertmarc riociguattreatmentforportopulmonaryhypertensionasubgroupanalysisfromthepatent12studies
AT mattsonjohn riociguattreatmentforportopulmonaryhypertensionasubgroupanalysisfromthepatent12studies
AT fritscharno riociguattreatmentforportopulmonaryhypertensionasubgroupanalysisfromthepatent12studies
AT krowkamichael riociguattreatmentforportopulmonaryhypertensionasubgroupanalysisfromthepatent12studies

Ejemplares similares